KUALA LUMPUR, Nov 13 (Bernama) -- On a video post on social media, a 32-year-old man who asked to be identified as Parab from Kedah comes on screen, fills a hypodermic needle with liquid from a vial and injects his belly. He then flexes for the camera.
In the captions, he calls the drug – which he identified as retatrutide in another post – a “game changer” for his quest to lose weight and be healthier.
Retatrutide, an experimental weight-loss drug developed by the United States (US) pharmaceutical giant Eli Lilly, is still in the development stage and has not been approved for sale or use anywhere in the world, including Malaysia. And yet, sales of retatrutide, called reta for short, have been front and centre in the news and in social media for months.
